Microcap Capricor soars on interim PhII DMD data showing functional benefit for older patients
With the interim analysis for its Phase II Duchenne muscular dystrophy, little Capricor Therapeutics was merely looking for a guidepost, a signal, a trend that the effects seen in an earlier trial can be replicated with a new dosing regimen and delivery method. Instead, the biotech found itself blessed with a basket of data points that seem to buck the natural history trend and separate the drug from placebo in a statistically significant way, more than doubling its tiny stock $CAPR in pre-market trading.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.